+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes



Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes



British Journal of Clinical Pharmacology 79(2): 330-336



In order to exert its pharmacodynamic effect, the diabetes drug metformin needs to be taken up into hepatocytes by the organic cation transporter (OCT) system. A recent in vitro study found that proton pump inhibitors (PPIs) inhibit OCT1, OCT2 and OCT3, suggesting that PPIs might reduce metformin's effectiveness. This pharmacoepidemiologic study looked for evidence of a clinical effect of such an interaction. This was an observational cohort study examining changes in glycosylated haemoglobin (HbA1c) with exposure to metformin and to PPIs as single agents and in combination. The aim was to assess evidence of a deleterious drug-drug interaction. PPIs did not reduce the effectiveness of metformin, and indeed were associated with a minimally better glycaemic response by - 0.06 HbA1c percentage points (95% confidence interval, -0.10, -0.01) in metformin initiators. Despite a mechanistic basis for a potential drug-drug interaction, we found no evidence of a deleterious interaction between PPIs and metformin.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260353

Download citation: RISBibTeXText

PMID: 25199921

DOI: 10.1111/bcp.12506


Related references

How May Proton Pump Inhibitors Impair Cardiovascular Health?. American Journal of Cardiovascular Drugs 16(3): 153-161, 2016

Effectiveness of proton pump inhibitors in the treatment of patients with endoscopic esophagitis. Medicinski Arhiv 64(6): 362-364, 2011

Increased use of proton pump inhibitors in patients with diabetes and neuropathy. Endocrine Practice 15(6): 653-654, 2010

Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metabolism and Disposition: the Biological Fate of Chemicals 42(7): 1174-1179, 2015

Effect of proton pump inhibitors on glycemic control in patients with diabetes. World Journal of Diabetes 6(10): 1122-1131, 2015

Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?. Osteoporosis International 27(4): 1675-1676, 2016

Metformin plus proton pump inhibitors therapy: the cobalamin deficiency challenge. European Review for Medical and Pharmacological Sciences 19(13): 2501-2502, 2016

Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clinical Gastroenterology and Hepatology 12(11): 1815-23.E2, 2015

Metformin and vitamin B12 deficiency: the role of H2 receptor antagonists and proton pump inhibitors. Age and Ageing 36(1): 110-1; Discussion 111, 2007

Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). Plos One 6(7): E22163-E22163, 2011

Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. Journal of Gastroenterology 46(1): 39-45, 2011

Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Current Medical Research and Opinion 20 Suppl 1(): S41-S51, 2004

Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 17(2): 225-233, January, 2003

Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. Acta Diabetologica 52(5): 873-880, 2015